ICD-10-CM Billable Code

M11.259

Other chondrocalcinosis, unspecified hip

Clinical Classification Guidelines

Medical Intelligence & Overview

Chondrocalcinosis, often known as calcium pyrophosphate dihydrate (CPPD) deposition disease, involves the buildup of calcium crystals within the cartilage of joints. When it affects the hip but is not classified under a specific subtype, it is categorized as 'other chondrocalcinosis, unspecified hip' with the ICD-10 code M11.259. This condition can cause joint pain, swelling, and reduced mobility, impacting quality of life. Understanding its causes, symptoms, and available management options can help patients and caregivers recognize and address this condition effectively.

Causes & Symptoms

Clinical Causes: Degeneration of joint cartilage over time Age-related changes leading to increased crystal deposition Genetic predispositions affecting cartilage metabolism Previous joint injuries or surgeries Metabolic disorders such as hyperparathyroidism or hemochromatosis Other underlying health conditions that influence calcium and phosphate balance

Key Symptoms: Joint pain and tenderness, especially during movement or in weight-bearing activities Swelling and inflammation around the affected hip Stiffness, making it difficult to move the joint fully Reduced range of motion in the hip joint Possible warmth and redness over the joint area Discomfort that may worsen with activity and improve with rest

Diagnostic & Treatment

Diagnosis Path: Diagnosing chondrocalcinosis involves a combination of clinical evaluation and imaging studies. Healthcare providers may conduct physical examinations to assess joint function and identify signs of inflammation. Imaging techniques such as X-rays are commonly used and can reveal characteristic calcification patterns within the cartilage. In some cases, joint fluid analysis via arthrocentesis is performed to detect calcium pyrophosphate crystals directly, confirming the diagnosis. Laboratory tests might be utilized to identify underlying metabolic or systemic causes that contribute to crystal deposition.

Treatment Protocols: Management of chondrocalcinosis focuses on relieving symptoms, maintaining joint function, and addressing any underlying conditions. Typical approaches include: - Pain relievers like nonsteroidal anti-inflammatory drugs (NSAIDs) - Corticosteroid injections to reduce inflammation - Physical therapy aimed at improving joint mobility and strength - Lifestyle modifications such as weight management and low-impact exercises - Addressing systemic conditions like hyperparathyroidism or hemochromatosis if identified - Surgical intervention, including joint replacement, may be considered in severe cases where conservative treatments fail to alleviate symptoms Consulting healthcare providers is essential for personalized treatment planning and monitoring the progression of the condition.

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is M11.259 a billable ICD-10 code?
Yes, M11.259 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report M11.259?
Clinical documentation must specify the nature of Other chondrocalcinosis, unspecified hip and any associated comorbidities for accurate reporting.

Cite this Clinical Reference